

Supporting Information

S1-S2 Figures and S1-S3 Tables


featuring the article

Model-based optimization of combination protocols for irradiation-insensitive cancers


by Beata Hat¹, Joanna Jaruszewicz-Błońska¹, and Tomasz Lipniacki¹

¹ Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland


Scientific Reports 2020



S1 Figure. Detailed representation of the full model based on [S1]. Arrow-headed dashed lines indicate transcriptional regulation, arrow-headed solid lines—protein transformation, circle-headed solid lines—positive influence, hammer-headed dotted lines—ubiquitination by Mdm2 leading to protein degradation. The subscripts n or c denote either nuclear or cytoplasmic localization of Mdm2. Bold ‘P’ and non-bold ‘U’ denote phosphorylated and unphosphorylated states of given residues, respectively. Mdm2 inhibitor is represented with red circle; pro-survival and cycle-promoting proteins are represented with blue boxes, pro-apoptotic proteins with yellow boxes, proteins promoting cell cycle arrest with green boxes, while the remaining proteins and protein complexes are left in grey boxes.



Legend to panels A-D



S2 Figure. Relative resistance to irradiation: normal versus PTEN-cancer (A, C) and Wip1-cancer (B, D) cells based on the deterministic model simulations. The inhibitor dose is given in IC_{50} units per single administration with respect to cancer cells for which 3-fold higher (A-B) or equal (C-D) specificity (with respect to normal cells) is assumed. In each panel two protocols with highest IR_{crit} ratio are marked with color lines (see Legend). Grey lines correspond to the other analyzed protocols (shown in Fig. 4A).

All parameters, excluding parameters governing inhibitor dynamics, come from our previous study [S1]. All reactants levels are given in molecules/cell; such representation enables stochastic simulations. Parameters governing inhibitor dynamics were chosen to reproduce experimental data shown in Zhang et al. [S2]. The maximal level of inhibitor in blood is achieved at approximately 2 hours after oral inhibitor delivery. After next 10 hours the inhibitor level decreases approximately ten-fold (see Fig 4). For the sake of simplicity processes of cellular import of inhibitor from blood and its binding with Mdm2 are lumped together into a single reaction with rate k_a . Analogously, inhibitor:Mdm2 complex dissociation is lumped with inhibitor export from cell to blood and described by a single reaction with rate k_d . Oral inhibitor delivery is instantaneous. Technical realization of such delivery is following: inhibitor administration time is set equal 10 seconds and the single dose, denoted by INH, is administered with rate $\text{INH}/10 \text{ s}^{-1}$. In the case of drip inhibitor delivery, a daily dose INH is given with rate $\text{INH}/24 \text{ h}^{-1}$. We assume that at any given time point the fraction of inhibitor molecules bound to Mdm2 is small; accordingly we neglect depletion of inhibitor due to Mdm2 binding.

Supporting Tables

S1 Table. Notation guide.

| Symbol | Description |
|--|--|
| Inhibitor dynamics | |
| $\text{INH}_{\text{Mdm2_oral}}$ | Mdm2 inhibitor administered orally |
| $\text{INH}_{\text{Mdm2_blood}}$ | Mdm2 inhibitor level in blood |
| $\text{Mdm2}_{\text{cyt_0p}} : \text{INH}_{\text{Mdm2_blood}}$ | complex of $\text{INH}_{\text{Mdm2_blood}}$ and cytoplasmic unphosphorylated Mdm2 |
| $\text{Mdm2}_{\text{cyt_2p}} : \text{INH}_{\text{Mdm2_blood}}$ | complex of $\text{INH}_{\text{Mdm2_blood}}$ and cyt. Mdm2 p'ylated at Ser166 and 186 |
| $\text{Mdm2}_{\text{nuc_2p}} : \text{INH}_{\text{Mdm2_blood}}$ | complex of $\text{INH}_{\text{Mdm2_blood}}$ and nuclear Mdm2 p'ylated at Ser166 and 186 |
| $\text{Mdm2}_{\text{nuc_3p}} : \text{INH}_{\text{Mdm2_blood}}$ | complex of $\text{INH}_{\text{Mdm2_blood}}$ and nuc. Mdm2 p'ylated at Ser166, 186 and 395 |
| Core module | |
| DNA_{DSB} | DNA damage due to IR: double strand breaks (DSBs) |
| ATM_u | unphosphorylated kinase ATM |
| ATM_p | ATM phosphorylated at Ser1981 (upon DNA DSBs) |
| $\text{Wip1}_{\text{gene_a}}, \text{Wip1}_{\text{gene_i}}$ | state of the Wip1 (PPM1D) gene: active(a)/inactive(i) |
| $\text{Wip1}_{\text{mRNA}}$ | Wip1 transcript |
| Wip1 | phosphatase Wip1 |
| SIAH1_u | unphosphorylated SIAH1 |
| SIAH1_p | SIAH1 phosphorylated at Ser19 |
| HIPK2 | kinase HIPK2 |
| $p53_{0p}$ | unphosphorylated p53 |
| $p53_{\text{ARRESTER}}$ | p53 phosphorylated at Ser15, Ser20 |
| $p53_{\text{KILLER}}$ | p53 phosphorylated at Ser15, Ser20 and additionally at Ser46 |
| $p53_{s46}$ | p53 phosphorylated at Ser46 only |
| $\text{Mdm2}_{\text{gene_a}}, \text{Mdm2}_{\text{gene_i}}$ | state of the Mdm2 gene: active(a)/inactive(i) |
| $\text{Mdm2}_{\text{mRNA}}$ | Mdm2 transcript |
| $\text{Mdm2}_{\text{cyt_0p}}$ | cytoplasmic, unphosphorylated Mdm2 |
| $\text{Mdm2}_{\text{cyt_2p}}$ | cytoplasmic Mdm2 phosphorylated at Ser166 and Ser186 |
| $\text{Mdm2}_{\text{nuc_2p}}$ | nuclear Mdm2 phosphorylated at Ser166 and Ser186 |
| $\text{Mdm2}_{\text{nuc_3p}}$ | nuclear Mdm2 phosph. at Ser166, 186 and additionally at Ser395 |
| PI3K | kinase PI3K |
| $\text{PTEN}_{\text{gene_a}}, \text{PTEN}_{\text{gene_i}}$ | state of the PTEN gene: active(a)/inactive(i) |
| $\text{PTEN}_{\text{mRNA}}$ | PTEN transcript |
| PIP2 | bi-phosphatidylinositol |
| PIP3 | tri-phosphatidylinositol |

| Akt_u | unphosphorylated AKT |
|--------------------------------|--|
| Akt_p | Akt phosphorylated at Thr308 |
| Apoptotic module | |
| $Bax_{gene_a}, Bax_{gene_i}$ | state of the Bax gene: active(a)/inactive(i) |
| Bax_{mRNA} | Bax transcript |
| Bax | unbound form of Bax |
| $Bclx_L$ | unbound form of Bcl-x _L |
| $Bax : Bclx_L$ | complex of Bax and Bcl-x _L |
| Bad_u | unbound, unphosphorylated Bad |
| Bad_p | Bad: unbound, phosphorylated at Ser75 and Ser99 |
| $Bcl-x_L : Bad_u$ | complex of Bcl-x _L and Bad _u |
| $14-3-3$ | unbound adapter protein 14-3-3 |
| $Bad_p : 14-3-3$ | complex of Bad _p and 14-3-3 |
| $proCasp$ | inactive caspase |
| $Casp$ | active caspase |
| Cell cycle arrest module | |
| $p21_{gene_a}, p21_{gene_i}$ | state of the p21 gene: active(a)/inactive(i) |
| $p21_{mRNA}$ | p21 transcript |
| $p21$ | unbound p21 |
| $CycE$ | unbound Cyclin E |
| $p21 : CycE$ | complex of p21 and Cyclin E |
| $Rb1_u$ | Rb1: unbound, unphosphorylated at Ser780 |
| $Rb1_p$ | Rb1: unbound, phosphorylated at Ser780 |
| $Rb1_u : E2F1$ | complex of unphosphorylated Rb1 and E2F1 |

S2 Table. Model parameters.

| Parameter | Symbol | Value | Remarks |
|------------------------------|---------------|----------------------------|--|
| Duration of the IR phase | IR_T | 600 [s] | — |
| Inhibitor dose | INH_{dose} | as given | — |
| Irradiation dose | IR_{Gy} | as given | — |
| Number of DSBs per 1Gy of IR | DSB_{Gy} | 10 [break/cell] | — |
| Maximal number of DSBs | DSB_{max} | 10^6 [break/cell] | — |
| Number of repair complexes | DSB_{rep} | 20 [mlc/cell] | — |
| Total amount of SIAH1 | $SIAH1_{tot}$ | 10^5 [mlc/cell] | $SIAH1_{tot} = SIAH1_u + SIAH1_p$ |
| Total amount of ATM | ATM_{tot} | 10^5 [mlc/cell] | $ATM_{tot} = ATM_u + ATM_p$ |
| Total amount of BclXL | $BclXL_{tot}$ | 10^5 [mlc/cell] | $Bclx_{L,tot} = Bclx_L + Bclx_L : Bad_u + Bclx_L : Bax$ |
| Total amount of Bad | Bad_{tot} | 6×10^4 [mlc/cell] | $Bad_{tot} = Bad_u + Bad_p + Bclx_L : Bad_u +$ $+ Bad_p : 14-3-3$ |
| Total amount of Rb1 | $Rb1_{tot}$ | 3×10^5 [mlc/cell] | $Rb1_{tot} = Rb1_p + Rb1_u + Rb1_u : E2F1$ |

| | | | |
|-------------------------------|----------------|----------------------------|--|
| Total amount of E2F1 | $E2F1_{tot}$ | 2×10^5 [mlc/cell] | $E2F1_{tot} = E2F1 + Rb1_u \cdot E2F1$ |
| Total amount of Akt | Akt_{tot} | 10^5 [mlc/cell] | $Akt_{tot} = Akt_u + Akt_p$ |
| Total amount of PIP3 and PIP2 | PIP_{tot} | 10^5 [mlc/cell] | $PIP_{tot} = PIP2 + PIP3$ |
| Total amount of 14-3-3 | $14-3-3_{tot}$ | 2×10^5 [mlc/cell] | $14-3-3_{tot} = 14-3-3 + Bad_p \cdot 14-3-3$ |

S3 Table. Reactions and reaction rate coefficients. All reactants levels are in molecules/cell.

| Reaction | Rate | Coeff. | Value |
|---|-------------------------------|----------|--|
| Inhibitor dynamics | | | |
| $\emptyset \xrightarrow{INH} INH_{Mdm2_oral}$ | $\frac{INH_{dose}}{duration}$ | duration | 10 s (oral single administration) 24×3600 s (drip administration) |
| $INH_{Mdm2_oral} \rightarrow INH_{Mdm2_blood}$ | dr_1 | dr_1 | $2.8 \times 10^{-4}/s$ |
| $INH_{Mdm2_blood} \rightarrow \emptyset$ | dr_2 | dr_2 | $0.7 \times 10^{-4}/s$ |
| $Mdm2_{cyt_0p} \xrightarrow{INH_{Mdm2_blood}} Mdm2_{cyt_0p} : INH_{Mdm2_blood}$ | $k_a \cdot INH_{Mdm2_blood}$ | k_a | k_d |
| $Mdm2_{cyt_2p} \xrightarrow{INH_{Mdm2_blood}} Mdm2_{cyt_2p} : INH_{Mdm2_blood}$ | | | |
| $Mdm2_{nuc_2p} \xrightarrow{INH_{Mdm2_blood}} Mdm2_{nuc_2p} : INH_{Mdm2_blood}$ | | | |
| $Mdm2_{nuc_3p} \xrightarrow{INH_{Mdm2_blood}} Mdm2_{nuc_3p} : INH_{Mdm2_blood}$ | | | |
| $Mdm2_{cyt_0p} \leftarrow Mdm2_{cyt_0p} : INH_{Mdm2_blood}$ | k_d | k_d | $4.6 \times 10^{-5}/s$ |
| $Mdm2_{cyt_2p} \leftarrow Mdm2_{cyt_2p} : INH_{Mdm2_blood}$ | | | |
| $Mdm2_{nuc_2p} \leftarrow Mdm2_{nuc_2p} : INH_{Mdm2_blood}$ | | | |
| $Mdm2_{nuc_3p} \leftarrow Mdm2_{nuc_3p} : INH_{Mdm2_blood}$ | | | |
| $Mdm2_{cyt_2p} : INH_{Mdm2_blood} \rightarrow Mdm2_{nuc_2p} : INH_{Mdm2_blood}$ | i_1 | i_1 | $10^{-3}/s$ |
| $Mdm2_{nuc_2p} : INH_{Mdm2_blood} \xrightarrow{ATM_p} Mdm2_{nuc_3p} : INH_{Mdm2_blood}$ | $p_6 \cdot ATM_p$ | p_6 | $10^{-8}/s$ |
| $Mdm2_{nuc_2p} : INH_{Mdm2_blood} \xleftarrow{Wip1} Mdm2_{nuc_3p} : INH_{Mdm2_blood}$ | $d_6 \cdot Wip1$ | d_6 | $10^{-10}/s$ |

| Core module | | | |
|--|---|---------------|-----------------------|
| $\emptyset \xrightarrow{IR} DNA_{DSB}$ | $h_1 \cdot \frac{DSB_{Gy} \cdot IR_{Gy}}{IR_T} \cdot (DSB_{max} - DNA_{DSB})$ | h_1 | $10^{-6}/s$ |
| $\emptyset \xrightarrow{Casp} DNA_{DSB}$ | | DSB_{Gy} | 10 |
| | | IR_T | $10 \times 60 s$ |
| | $h_2 \cdot Casp \cdot (DSB_{max} - DNA_{DSB})$ | DSB_{max} | 10^6 |
| | | h_2 | $10^{-13}/s$ |
| $DNA_{DSB} \rightarrow \emptyset$ | $\frac{rep}{DNA_{DSB} + DSB_{rep}}$ | rep | $10^{-3}/s$ |
| | | DNA_{DSB} | 20 |
| $ATM_u \xrightarrow{DSB} ATM_p$ | $p_1 \cdot \frac{DNA_{DSB}^h}{M_1^h + DNA_{DSB}^h}$ | p_1 | $3 \times 10^{-4}/s$ |
| | | h | 2 |
| | | M_1 | 5 |
| $ATM_u \xleftarrow{Wip1} ATM_p$ | $d_1 \cdot Wip1$ | d_1 | $10^{-8}/s$ |
| $SIAH-1_u \xrightarrow{ATM_p} SIAH-1_p$ | $p_2 \cdot ATM_p$ | p_2 | $10^{-8}/s$ |
| $SIAH-1_u \leftarrow SIAH-1_p$ | d_2 | d_2 | $3 \times 10^{-5}/s$ |
| $\emptyset \rightarrow HIPK2$ | s_8 | s_8 | 30/s |
| $HIPK2 \xrightarrow{Mdm2_{nuc_2p}, SIAH-1_u} \emptyset$ | $g_7 \cdot (SIAH-1_u + Mdm2_{nuc_2p})^2$ | g_7 | $10^{-13}/s$ |
| $Wip1_{gene_i} \rightarrow Wip1_{gene_a}$ | q_{0_Wip1} | q_{0_Wip1} | $10^{-5}/s$ |
| $Wip1_{gene_i} \xrightarrow{p53_{ARRESTER}} Wip1_{gene_a}$ | $q_{1_Wip1} \cdot p53_{ARRESTER}^h$ | q_{1_Wip1} | $3 \times 10^{-13}/s$ |
| | | h | 2 |
| $Wip1_{gene_i} \leftarrow Wip1_{gene_a}$ | q_2 | q_2 | $3 \times 10^{-3}/s$ |
| $\emptyset \xrightarrow{Wip1_{gene_a}} Wip1_{mRNA}$ | $s_1 \cdot Wip1_{gene_a}$ | s_1 | 0.1/s |
| $Wip1_{mRNA} \rightarrow \emptyset$ | g_1 | g_1 | $3 \times 10^{-4}/s$ |
| $\emptyset \rightarrow Wip1$ | $t_1 \cdot Wip1_{mRNA}$ | t_1 | 0.1/s |
| $Wip1 \rightarrow \emptyset$ | g_8 | g_8 | $3 \times 10^{-4}/s$ |
| $\emptyset \rightarrow p53_{0p}$ | s_6 | s_6 | 300/s |
| $p53_{0p} \rightarrow \emptyset$ | g_{101} | g_{101} | $10^{-5}/s$ |
| $p53_{s46} \rightarrow \emptyset$ | | | |
| $p53_{ARRESTER} \rightarrow \emptyset$ | | | |
| $p53_{KILLER} \rightarrow \emptyset$ | | | |
| $p53_{0p} \xrightarrow{Mdm2_{nuc_2p}} \emptyset$ | $g_{11} \cdot Mdm2_{nuc_2p}^2$ | g_{11} | $10^{-11}/s$ |
| $p53_{ARRESTER} \xrightarrow{Mdm2_{nuc_2p}} \emptyset$ | $g_{12} \cdot Mdm2_{nuc_2p}^2$ | g_{12} | $10^{-13}/s$ |
| $p53_{KILLER} \xrightarrow{Mdm2_{nuc_2p}} \emptyset$ | | | |
| $p53_{s46} \xrightarrow{Mdm2_{nuc_2p}} \emptyset$ | | | |
| $p53_{0p} \xrightarrow{ATM_p} p53_{ARRESTER}$ | $p_3 \cdot ATM_p$ | p_3 | $3 \times 10^{-8}/s$ |
| $p53_{s46} \xrightarrow{ATM_p} p53_{KILLER}$ | | | |
| $p53_{0p} \leftarrow p53_{ARRESTER}$ | d_3 | d_3 | $10^{-4}/s$ |
| $p53_{s46} \leftarrow p53_{KILLER}$ | | | |

| | | | |
|--|--------------------------------------|----------------------|------------------------------|
| $p53_{0p} \xrightarrow{HIPK2} p53_{s46}$ | $p_4 \cdot HIPK2$ | p_4 | $10^{-10}/s$ |
| $p53_{ARRESTER} \xrightarrow{HIPK2} p53_{KILLER}$ | | | |
| $p53_{0p} \xleftarrow{Wip1} p53_{s46}$ | $d_4 \cdot Wip1$ | d_4 | $10^{-10}/s$ |
| $p53_{ARRESTER} \xleftarrow{Wip1} p53_{KILLER}$ | | | |
| $Mdm2_{gene_i} \rightarrow Mdm2_{gene_a}$ | q_{0_Mdm2} | q_{0_Mdm2} | $10^{-4}/s$ |
| $Mdm2_{gene_i} \xrightarrow{p53_{ARRESTER}} Mdm2_{gene_a}$ | $q_{1_Mdm2} \cdot p53_{ARRESTER}^h$ | q_{1_Mdm2} h | $3 \times 10^{-13}/s$ 2 |
| $Mdm2_{gene_i} \leftarrow Mdm2_{gene_a}$ | q_2 | q_2 | $3 \times 10^{-3}/s$ |
| $\emptyset \xrightarrow{Mdm2_{gene_a}} Mdm2_{mRNA}$ | $s_3 \cdot Mdm2_{gene_a}$ | s_3 | $0.1/s$ |
| $Mdm2_{mRNA} \rightarrow \emptyset$ | g_3 | g_3 | $3 \times 10^{-4}/s$ |
| $\emptyset \rightarrow Mdm2_{cyt_0p}$ | $t_3 \cdot Mdm2_{mRNA}$ | t_3 | $0.1/s$ |
| $Mdm2_{cyt_0p} \xrightarrow{AKT_p} Mdm2_{cyt_2p}$ | $p_5 \cdot Akt_p$ | p_5 | $10^{-8}/s$ |
| $Mdm2_{cyt_0p} \leftarrow Mdm2_{cyt_2p}$ | d_5 | d_5 | $10^{-4}/s$ |
| $Mdm2_{cyt_2p} \rightarrow Mdm2_{nuc_2p}$ | i_1 | i_1 | $10^{-3}/s$ |
| $Mdm2_{nuc_2p} \xrightarrow{ATM_p} Mdm2_{nuc_3p}$ | $p_6 \cdot ATM_p$ | p_6 | $10^{-8}/s$ |
| $Mdm2_{nuc_2p} \xleftarrow{Wip1} Mdm2_{nuc_3p}$ | $d_6 \cdot Wip1$ | d_6 | $10^{-10}/s$ |
| $Mdm2_{cyt_0p} \rightarrow \emptyset$ | g_{14} | g_{14} | $10^{-4}/s$ |
| $Mdm2_{cyt_2p} \rightarrow \emptyset$ | g_{15} | g_{15} | $3 \times 10^{-5}/s$ |
| $Mdm2_{nuc_2p} \rightarrow \emptyset$ | | | |
| $Mdm2_{nuc_3p} \rightarrow \emptyset$ | g_{16} | g_{16} | $10^{-4}/s$ |
| $PTEN_{gene_i} \rightarrow PTEN_{gene_a}$ | q_{0_PTEN} | q_{0_PTEN} | $10^{-5}/s$ |
| $PTEN_{gene_i} \xrightarrow{p53_{KILLER}} PTEN_{gene_a}$ | $q_{1_PTEN} \cdot p53_{KILLER}^h$ | q_{1_PTEN} h | $3 \times 10^{-13}/s$ 2 |
| $PTEN_{gene_i} \leftarrow PTEN_{gene_a}$ | q_2 | q_2 | $3 \times 10^{-3}/s$ |
| $\emptyset \xrightarrow{PTEN_{gene_a}} PTEN_{mRNA}$ | $s_2 \cdot PTEN_{gene_a}$ | s_2 | $0.03/s$ |
| $PTEN_{mRNA} \rightarrow \emptyset$ | g_2 | g_2 | $3 \times 10^{-4}/s$ |
| $\emptyset \rightarrow PTEN$ | $t_2 \cdot PTEN_{mRNA}$ | t_2 | $0.1/s$ |
| $PTEN \rightarrow \emptyset$ | g_6 | g_6 | $3 \times 10^{-5}/s$ |
| $PIP2 \xrightarrow{PI3K} PIP3$ | $p_8 \cdot PIP3$ | p_8 | $3 \times 10^{-9}/s$ |
| $PIP2 \xleftarrow{PTEN} PIP3$ | $d_7 \cdot PTEN$ | d_7 | $3 \times 10^{-7}/s$ |
| $Akt_u \xrightarrow{PIP3} Akt_p$ | $p_{12} \cdot PIP3$ | p_{12} | $10^{-9}/s$ |
| $Akt_u \leftarrow Akt_p$ | d_8 | d_8 | 10^{-4} |
| Apoptotic module | | | |
| $Bax_{gene_i} \rightarrow Bax_{gene_a}$ | q_{0_Bax} | q_{0_Bax} | $10^{-5}/s$ |

| | | | |
|--|---|-----------------------|---------------------------------------|
| $Bax_{gene_i} \xrightarrow{p53^{KILLER}} Bax_{gene_a}$ | $q_{1_Bax} \cdot p53^h_{KILLER}$ | q_{1_Bax} h | $3 \times 10^{-13}/s$ 2 |
| $Bax_{gene_i} \leftarrow Bax_{gene_a}$ | q_2 | q_2 | $3 \times 10^{-3}/s$ |
| $\emptyset \xrightarrow{Bax_{gene_a}} Bax_{mRNA}$ | $s_4 \cdot Bax_{gene_a}$ | s_4 | $0.03/s$ |
| $Bax_{mRNA} \rightarrow \emptyset$ | g_4 | g_4 | $3 \times 10^{-4}/s$ |
| $\emptyset \rightarrow Bax$ | $t_4 \cdot Bax_{mRNA}$ | t_4 | $0.1/s$ |
| $Bax \rightarrow \emptyset$ | g_9 | g_9 | $10^{-4}/s$ |
| $Bax + Bclx_L \rightarrow Bax:Bclx_L$ | b_1 | b_1 | $3 \times 10^{-5}/s$ |
| $Bax + Bclx_L \leftarrow Bax:Bclx_L$ | u_1 | u_1 | $10^{-3}/s$ |
| $Bax:Bclx_L \rightarrow Bclx_L$ | g_{16} | g_{16} | $10^{-4}/s$ |
| $Bclx_L + Bad_u \rightarrow Bclx_L:Bad_u$ | b_2 | b_2 | $3 \times 10^{-3}/s$ |
| $Bclx_L + Bad_u \leftarrow Bclx_L:Bad_u$ | u_2 | u_2 | $10^{-3}/s$ |
| $Bclx_L:Bad_u \xrightarrow{Akt_p} Bclx_L$ | $p_7 \cdot Akt_p$ | p_7 | $3 \times 10^{-9}/s$ |
| $Bad_u \xrightarrow{AKT_p} Bad_p$ | $p_7 \cdot Akt_p$ | p_7 | $3 \times 10^{-9}/s$ |
| $Bad_u \leftarrow Bad_p$ | d_9 | d_9 | $3 \times 10^{-5}/s$ |
| $Bad_u + 14-3-3 \leftarrow Bad_p + 14-3-3$ | | | |
| $Bad_p + 14-3-3 \rightarrow Bad_p:14-3-3$ | b_3 | b_3 | $3 \times 10^{-3}/s$ |
| $Bad_p + 14-3-3 \leftarrow Bad_p:14-3-3$ | u_3 | u_3 | $10^{-3}/s$ |
| $\emptyset \rightarrow proCasp$ | s_7 | s_7 | $30/s$ |
| $proCasp \xrightarrow{Bax, Casp} Casp$ | $a_1 \cdot Bax + a_2 \cdot Casp^2$ | a_1 a_2 | $3 \times 10^{-10}/s$ $10^{-12}/s$ |
| $proCasp \rightarrow \emptyset$ | | | |
| $Casp \rightarrow \emptyset$ | g_{17} | g_{17} | $3 \times 10^{-4}/s$ |
| Cell cycle arrest module | | | |
| $p21_{gene_i} \rightarrow p21_{gene_a}$ | q_{0_p21} | q_{0_p21} | $10^{-5}/s$ |
| $p21_{gene_i} \xrightarrow{p53^{ARRESTER}} p21_{gene_a}$ | $q_{1_p21} \cdot p53^h_{ARRESTER}$ | q_{1_p21} h | $3 \times 10^{-13}/s$ 2 |
| $p21_{gene_i} \leftarrow p21_{gene_a}$ | q_2 | q_2 | $3 \times 10^{-3}/s$ |
| $\emptyset \xrightarrow{p21_{gene_a}} p21_{mRNA}$ | $s_5 \cdot p21_{gene_a}$ | s_5 | $0.1/s$ |
| $p21_{mRNA} \rightarrow \emptyset$ | g_5 | g_5 | $3 \times 10^{-4}/s$ |
| $\emptyset \rightarrow p21$ | $t_5 \cdot p21_{mRNA}$ | t_5 | $0.1/s$ |
| $p21 \rightarrow \emptyset$ | g_{19} | g_{19} | $3 \times 10^{-4}/s$ |
| $\emptyset \xrightarrow{E2F1} CycE$ | $s_9 \cdot \frac{E2F1^h}{M_3^h + E2F1^h}$ | s_9 h M_3 | $30/s$ 2 2×10^5 |
| $\emptyset \rightarrow CycE$ | s_{10} | s_{10} | $3/s$ |
| $p21 + CycE \rightarrow p21:CycE$ | b_5 | b_5 | $10^{-5}/s$ |
| $p21 + CycE \leftarrow p21:CycE$ | u_6 | u_6 | $10^{-4}/s$ |
| $CycE \rightarrow \emptyset$ | g_{20} | g_{20} | $10^{-4}/s$ |

| | | | |
|--|------------------------------|----------------------|-----------------------|
| $Rb1_u \xrightarrow{CycE} Rb1_p$ | $p_9 \cdot CycE$ | p_9 | $3 \times 10^{-6}/s$ |
| $Rb1_u \leftarrow Rb1_p$ | $\frac{d_{12}}{M_2 + Rb1_p}$ | $\frac{d_{12}}{M_2}$ | $\frac{10^4/s}{10^5}$ |
| $Rb1_u + E2F1 \rightarrow Rb1_u : E2F1$ | b_4 | b_4 | $10^{-5}/s$ |
| $Rb1_u + E2F1 \leftarrow Rb1_u : E2F1$ | u_5 | u_5 | $10^{-4}/s$ |
| $Rb1_u : E2F1 \xrightarrow{CycE} Rb1_p + E2F1$ | $p_{10} \cdot CycE$ | p_{10} | $3 \times 10^{-6}/s$ |

Supplementary references

- S1. Hat B, Kochańczyk M, Bogdał MN, Lipniacki T. Feedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System. Meier-Schellersheim M, editor. PLoS Comput Biol. 2016;12: e1004787. doi:10.1371/journal.pcbi.1004787
- S2. Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, et al. Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration. Drug Metab Dispos. 2011;39: 15–21. doi:10.1124/dmd.110.035915